St. Luke’s Health Network
SLUHN receives Civica Rx drug shipment
St. Luke’s University Health Network received its first shipment of injectable drugs from Civica Rx, a nationwide consortium the Network joined last year to combat chronic shortages and rising prices of widely used generic medications.
Civica Rx is a nonprofit generic drug company that aims to circumvent traditional supply chains by producing in-demand drugs and selling them at fair and sustainable prices to consortium members.
David Herold, St. Luke’s Senior Director of Business Development & Planning, said, “This first shipment is an important milestone for St. Luke’s and signals that Civica Rx is making good on its promise to provide reliable and affordable access to mission critical drugs.”
The St. Luke’s shipment from Civica Rx includes drugs that are critical to its mission, including the antibiotics Vancomycin and Daptomycin and the overdose reversing drug Naloxone. Herold said many common drugs are manufactured by one or two generic companies, a situation that leads to price hikes due to little competition. It also spurs shortages when weather-related or unforeseen events hit a lone manufacturing site producing a drug.